scholarly journals Postoperative adjuvant therapy for resectable gastric cancer

1994 ◽  
Vol 3 (2) ◽  
pp. 121-125,72
Author(s):  
Kyoji Ogoshi ◽  
Yasuo Kajiura ◽  
Kenji Nakamura ◽  
Yasuo Miyaji ◽  
Kunihiro Iwata ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Postoperative Adjuvant Therapy ◽  
Resectable Gastric Cancer

TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. TPS4141-TPS4141 ◽  
Author(s):  
Trevor Leong ◽  
Mark Smithers ◽  
Michael Michael ◽  
Val Gebski ◽  
Alex Boussioutas ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Phase Ii ◽  
Preoperative Chemotherapy ◽  
Gastroesophageal Junction ◽  
Phase Iii ◽  
Standards Of Care ◽  
Current Status ◽  
Quality Assurance Program ◽  
Resectable Gastric Cancer

TPS4141 Background: Optimal management of patients with resectable gastric cancer remains unknown. Since the INT0116 and MAGIC trials, there are 2 standards of care for adjuvant therapy: postoperative chemoradiotherapy (CRT) and perioperative ECF chemotherapy. The important question arising from these studies is whether CRT is superior to chemotherapy alone as adjuvant therapy. This randomized phase II/III trial will compare CRT to chemotherapy alone in the preoperative setting. Methods: Patients with resectable adenocarcinoma of the stomach or gastroesophageal junction will be randomized to receive either preoperative chemotherapy alone (ECFx3 as per MAGIC regimen) or preoperative CRT (ECFx2 followed by 45Gy of radiation with concurrent 5-FU). Following surgery, both groups will receive 3 further cycles of ECF. The trial is being conducted in two Parts; Part I (phase II component) will recruit 120 patients with the aim of demonstrating sufficient efficacy and safety of preoperative CRT, as well as trial feasibility. Part II (phase III component) will recruit a further 632 patients to provide a total of 752. The primary endpoint for Part I is pathological complete response rate, and for Part 2 it is overall survival. The trial includes formal quality of life and biological sub-studies. In addition, the trial incorporates a rigorous quality assurance program that includes real time central review of radiotherapy plans and central review of surgical technique. Current status: This study is an international, intergroup trial led by the Australasian Gastro-Intestinal Trials Group (AGITG), in collaboration with the Trans-Tasman Radiation Oncology Group (TROG), European Organisation for Research and Treatment of Cancer (EORTC) and the NCIC Clinical Trials Group. To date, 36 patients have been recruited from 20 sites in Australia and New Zealand; European and Canadian sites will commence recruitment in 2012.

Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer

2006 ◽  
Vol 6 (6) ◽  
pp. 931-939 ◽  
Author(s):  
Evangelos Briasoulis ◽  
Theodore Liakakos ◽  
Lefkothea Dova ◽  
Michael Fatouros ◽  
Pericles Tsekeris ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Postoperative Adjuvant Therapy

Adjuvant therapy in resectable gastric cancer—the CRITICS trial – Authors' reply

2018 ◽  
Vol 19 (7) ◽  
pp. e331
Author(s):  
Annemieke Cats ◽  
Karolina Sikorska ◽  
Marcel Verheij
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Resectable Gastric Cancer

Adjuvant therapy in resectable gastric cancer—the CRITICS trial

2018 ◽  
Vol 19 (7) ◽  
pp. e330 ◽  
Author(s):  
Jingwen Wang ◽  
Chao Li ◽  
Xiaodong Zhu ◽  
Ji Zhu
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Resectable Gastric Cancer
Sign in / Sign up

Export Citation Format

Share Document